| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Kevin M Sullivan | |
| Peter S Kozuch | |||
| P2860 | cites work | Oncogenes and Cancer | Q22248112 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Genetic alterations during colorectal-tumor development | Q28281200 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| EGF-ERBB signalling: towards the systems level | Q29619032 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| NRAS mutations are rare in colorectal cancer | Q34091172 | ||
| Receptors for epidermal growth factor and other polypeptide mitogens | Q34163558 | ||
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial | Q34614245 | ||
| Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer | Q34737137 | ||
| American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy | Q34935716 | ||
| Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment | Q35090966 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer | Q36614114 | ||
| ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. | Q36623819 | ||
| Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines | Q36628049 | ||
| Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. | Q53554133 | ||
| RAS oncogenes: the first 30 years. | Q55036584 | ||
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. | Q55043614 | ||
| The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis | Q57770590 | ||
| Prevalence of ras gene mutations in human colorectal cancers | Q59088716 | ||
| BRAFMutation in Metastatic Colorectal Cancer | Q61481269 | ||
| Epidermal growth factor | Q68508116 | ||
| Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy | Q79899761 | ||
| First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer | Q80534295 | ||
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 | ||
| Determinants of RASistance to anti-epidermal growth factor receptor agents | Q80812234 | ||
| Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study | Q81311015 | ||
| Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer | Q81323824 | ||
| Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer | Q81895464 | ||
| Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases | Q82657420 | ||
| High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice | Q82839912 | ||
| Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer | Q83170881 | ||
| Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy | Q85057057 | ||
| Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 | ||
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. | Q37330719 | ||
| Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer | Q37378581 | ||
| Targeting the RAF-MEK-ERK pathway in cancer therapy | Q37393116 | ||
| Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors | Q37629722 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy | Q39625657 | ||
| Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models | Q39755197 | ||
| Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer | Q40287803 | ||
| Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy | Q40293653 | ||
| Dimerization of cell surface receptors in signal transduction | Q40579106 | ||
| Drug discovery: inhibitors that activate | Q43125789 | ||
| A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer | Q43204708 | ||
| KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 | ||
| Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. | Q43503018 | ||
| AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis | Q43833515 | ||
| A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer | Q44093928 | ||
| Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | Q44907727 | ||
| K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. | Q46022088 | ||
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. | Q46034442 | ||
| Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer | Q46068553 | ||
| Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. | Q46170948 | ||
| Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. | Q46190706 | ||
| Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. | Q46250628 | ||
| Colorectal cancer: mutations in a signalling pathway | Q46644995 | ||
| Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer | Q46658474 | ||
| Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092). | Q46659120 | ||
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 | ||
| A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. | Q46755325 | ||
| Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma | Q46816802 | ||
| Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma | Q46856639 | ||
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer | Q46892017 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 219309 | |
| P577 | publication date | 2011-03-15 | |
| P1433 | published in | Pathology Research International | Q26853836 |
| P1476 | title | Impact of KRAS Mutations on Management of Colorectal Carcinoma | |
| P478 | volume | 2011 |
| Q36321184 | Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer |
| Q36113663 | High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer |
| Q37481713 | Metastatic colorectal cancer-prolonging overall survival with targeted therapies |
| Q41098499 | MicroRNA-645 is an oncogenic regulator in colon cancer. |
| Q35213124 | Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer |
| Q34135178 | Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q34526671 | Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines |
Search more.